I8B-FH-ITSD - ClinicalTrials.gov - NCT03952130
I8B-FH-ITSD - ClinicalTrials.gov - NCT03952130
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year
Participants must have Hemoglobin A1c (HbA1c) of ≥7.0 and ≤10.0%
Participants must have been treated for at least 90 days prior to screening with either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at least twice daily
Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter (kg/m2)
Participants must NOT
Participants must not have used other anti-hyperglycemic medications or therapies (inhaled, oral or injectable) except for metformin within 90-days of screening
Participants must not have had more than 1 severe hypoglycemic episode within 6 months of screening
Participants must not have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
350
Trial Dates
May 2019 - February 2022
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year
Participants must have Hemoglobin A1c (HbA1c) of ≥7.0 and ≤10.0%
Participants must have been treated for at least 90 days prior to screening with either multiple daily injection(s) (MDI) or premixed analog/human insulin regimens at least twice daily
Participants must have body mass index (BMI) of ≤35.0 kilograms per square meter (kg/m2)
Participants must NOT
Participants must not have used other anti-hyperglycemic medications or therapies (inhaled, oral or injectable) except for metformin within 90-days of screening
Participants must not have had more than 1 severe hypoglycemic episode within 6 months of screening
Participants must not have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
350
Trial Dates
May 2019 - February 2022
Trial Phase
3
Trial Locations
Hide locations not currently recruiting